Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $1.56 on Tuesday, reaching $93.59. The company’s stock had a trading volume of 3,138,661 shares, compared to its average volume of 4,872,212. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $53.89 billion, a P/E ratio of 53.79, a PEG ratio of 2.25 and a beta of 0.85. The stock has a 50-day moving average price of $88.38 and a 200-day moving average price of $84.20. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Piper Sandler restated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. UBS Group started coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Finally, Evercore reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the first quarter worth $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $26,000. Finally, TrinityBridge Ltd acquired a new position in Edwards Lifesciences in the second quarter valued at about $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.